Fractures in adults on systemic steroid therapy: which prophylaxis?
Abstract
(1) Systemic steroid therapy leads to a loss of bone density after a few months. The loss is at least partly reversible on treatment cessation. Together with age, the underlying disease, and reduced mobility, systemic steroid therapy is a risk factor for fractures. (2) There are no treatments with proven efficacy in the prevention of fractures among patients on systemic steroid therapy. Prevention is thus based on restricting steroid therapy to situations where the benefits are likely to outweigh the risks. (3) The first preventive measure is to encourage adequate calcium intake, as for all subjects at risk of osteoporosis. There is no firm evidence that all patients on steroids require medicinal calcium supplementation. (4) Some treatments slow the decline in bone density associated with steroid therapy, but none has a demonstrated preventive effect on symptomatic fractures. This is the case of the calcium + vitamin D combination, which has the best risk-benefit ratio. Two diphosphonates and, in postmenopausal women, hormone replacement therapy, also have a positive effect on bone density.
Read the paper
Related studies
- Effectiveness of Bisphosphonates and Denosumab on Risk of Vertebral Fractures in Prostate Cancer Patients Under Androgen Deprivation Therapies: A Real-World Prospective Study
- Osteoporosis-related fractures after spinal cord injury: a retrospective study from Brazil
- Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men
- Lack of Association between Vitamin D Insufficiency and Cardiovascular or Fracture Risk: A UK Biobank Study
- Muscle strength and body composition are clinical indicators of osteoporosis
- Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.